Item 5.02. Departure of Directors or Certain Officers; Election of Directors;


           Appointment of Certain Officers; Compensatory Arrangements of Certain
           Officers.

On December 19, 2019, Aimmune Therapeutics, Inc. ("Aimmune" or the "Company") entered into a letter agreement with Stephen G. Dilly, M.B.B.S., Ph.D., former President and Chief Executive Officer of the Company (the "Letter Agreement"), which further amends the Transition and Separation Agreement dated, November 5, 2017, between the Company and Dr. Dilly, as amended in December 2018 and June 2019. Under the Letter Agreement, Dr. Dilly will continue to serve the Company as a Special Advisor through June 30, 2020 and receive a base salary of $12,000 per year. Dr. Dilly has been serving the Company as a Special Advisor since the expiration of his full-time employment as the Company's Senior Vice President, Clinical Science on September 30, 2019 pursuant to the previous letter agreement, dated June 13, 2019, between the Company and Dr. Dilly.

The foregoing description of the material terms of the Letter Agreement is qualified in its entirety by the full text of the Letter Agreement, which is attached hereto as Exhibit 10.1, and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.




(d) Exhibits

 Exhibit
   No.           Description

   10.1            Letter Agreement, dated December 19, 2019, between the Company and
                 Stephen G. Dilly, M.B.B.S., Ph.D.

   104           Cover Page Interactive Data File (embedded within the Inline XBRL
                 document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses